• Hope and hype: Inside the push for wearable diabetes technology

    on April 2nd, 2018
    Want to make a billion dollars? Here’s a hot tip: Invent wearable technology that detects diabetes, measures glucose levels, and determines how much insulin is needed – all without the need for a single drop of blood. If you accept this mission, there’s a catch: You’ll have a whole bunch of [...]
  • Think about breast cancer surveillance for transgender patients

    on March 30th, 2018
    REPORTING FROM ENDO 2018 CHICAGO (FRONTLINE MEDICAL NEWS) – Both transgender men and transgender women had an increased risk of breast cancer compared with a male, but not a female, reference population, said Christel de Blok, MD, sharing results of a Dutch national study. The study included 3,078[...]
  • Prior bariatric surgery may lead to IBD

    on March 30th, 2018
    FROM ALIMENTARY PHARMACOLOGY AND THERAPEUTICS Bariatric surgery increases the risk of new-onset inflammatory bowel disease (IBD), according to a case series and national database study. “A past history of bariatric surgery, but not recent surgery, was associated with both new-onset” Crohn’s di[...]
  • Robocalls increase diabetic retinopathy screenings in low-income patients

    on March 29th, 2018
    REPORTING FROM ENDO 2018 CHICAGO (FRONTLINE MEDICAL NEWS) – Sending robocall reminders increased diabetic retinopathy screenings significantly among low-income, minority patients, according to a presentation at the annual meeting of the Endocrine Society. Patients with diabetes require routine dia[...]
  • FDA approves highest capacity insulin pen

    on March 28th, 2018
    The Food and Drug Administration has approved Toujeo (insulin glargine 300 units/mL) Max SoloStar, a prefilled and disposable pen. This will be the highest capacity long-acting insulin pen to be available commercially, according to a company press release. The Max SoloStar pen holds more than 900 un[...]
  • Dexcom G6 gets FDA nod

    on March 28th, 2018
    The first integrated continuous glucose monitoring system suitable for patients as young as 2 years has received market clearance from the Food and Drug Administration. The Dexcom G6 is about 28% smaller than its predecessor, the G5, can be worn for up to 10 days – 43% longer than the G5 – and d[...]
  • Declining androgen levels correlated with increased frailty

    on March 27th, 2018
    REPORTING FROM ENDO 2018 CHICAGO (FRONTLINE MEDICAL NEWS) – Declining androgen levels are associated with deteriorating physical function and increased frailty in aging men, according to a study presented at the annual meeting of the Endocrine Society. The findings provide more evidence of the rel[...]
  • Diabetes does its part to increase health care costs

    on March 27th, 2018
    FROM DIABETES CARE The total direct and indirect costs of diabetes jumped over 25% from 2012 to 2017, which was enough to make it “the most costly chronic illness in the country,” the American Diabetes Association said. The estimated total economic burden of diabetes went from an inflation-adjus[...]
  • Oral SGLT-2 inhibitor reduced liver fat in diabetics with NAFLD

    on March 27th, 2018
    REPORTING FROM ENDO 2018 CHICAGO (FRONTLINE MEDICAL NEWS) – Empagliflozin, an oral sodium-glucose cotransporter 2 (SGLT-2), reduced liver fat by 5% and improved ALT in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus, according to a study presented at the annual [...]
  • Obesity in adults continues to rise

    on March 26th, 2018
    FROM JAMA Obesity and severe obesity rose significantly in adults but not in children from 2007 to 2016, according to data from the National Health and Nutrition Examination Survey. The age-standardized prevalence of obesity – defined as a body mass index of 30 or more – among adults aged 20 yea[...]
  • Efavirenz-based ART may hamper vaginal ring contraception

    on March 24th, 2018
    REPORTING FROM CROI 2018 BOSTON (FRONTLINE MEDICAL NEWS) – Efavirenz-based antiretroviral therapy may significantly impair the effectiveness of vaginal ring contraceptives, investigators reported. Over a 21-day period, levels of estrogen among women who used a vaginal ring (NuvaRing) while on efav[...]
  • DPP-4 inhibitors increase IBD risk in diabetes

    on March 21st, 2018
    FROM THE BMJ Dipeptidyl peptidase-4 inhibitors are associated with a 75% increase in the risk of inflammatory bowel disease (IBD) in individuals with type 2 diabetes, a study has found. Researchers reported the results of an observational cohort study of 141,170 patients with type 2 diabetes newly t[...]
  • SGLT2 inhibitors cut cardiovascular outcomes regardless of region

    on March 20th, 2018
    REPORTING FROM ACC 18 ORLANDO (FRONTLINE MEDICAL NEWS) – Cardiovascular outcomes were significantly more favorable with sodium glucose cotransporter-2 inhibitors compared with other glucose-lowering drugs, according to data from more than 400,000 type 2 diabetes patients in the Middle East, Asia P[...]
Back to top